79 related articles for article (PubMed ID: 23301646)
1. [Cost analysis of XELOX and FOLFOX-4 chemotherapy regimens for colorectal carcinoma].
Büchler T; Nohejlová Medková A; Kupec M; Bláha M; Pavlík T; Dušek L; Abrahámová J
Klin Onkol; 2012; 25(6):440-4. PubMed ID: 23301646
[TBL] [Abstract][Full Text] [Related]
2. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
[TBL] [Abstract][Full Text] [Related]
3. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Tse VC; Ng WT; Lee V; Lee AW; Chua DT; Chau J; McGhee SM
BMC Cancer; 2011 Jul; 11():288. PubMed ID: 21740590
[TBL] [Abstract][Full Text] [Related]
4. Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer.
Xie Q; Wen F; Wei YQ; Deng HX; Li Q
Colorectal Dis; 2013 Aug; 15(8):958-62. PubMed ID: 23506229
[TBL] [Abstract][Full Text] [Related]
5. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
[TBL] [Abstract][Full Text] [Related]
8. Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Pettersson K; Carlsson G; Holmberg C; Sporrong SK
Acta Oncol; 2012 Sep; 51(7):840-8. PubMed ID: 22937953
[TBL] [Abstract][Full Text] [Related]
9. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
Miyazaki Y; Harada T; Akase T; Arakawa I; Inoue T
Clin Ther; 2009; 31 Pt 2():2433-41. PubMed ID: 20110051
[TBL] [Abstract][Full Text] [Related]
10. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Rittweger K; Gilberg F; Saltz L
Br J Cancer; 2011 Jun; 105(1):58-64. PubMed ID: 21673685
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Lu GC; Fang F; Li DC
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):152-5. PubMed ID: 20403249
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
13. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Kandutsch S; Klinger M; Hacker S; Wrba F; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2008 Nov; 34(11):1231-6. PubMed ID: 18272318
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
15. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
18. [Changes of lymphocyte subsets before and after chemotherapy in colorectal carcinoma patients].
Zhang GQ; Zhao H; Wen XY; Li JY; Wu LL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):155-60. PubMed ID: 23643003
[TBL] [Abstract][Full Text] [Related]
19. XELOX in colorectal cancer: a convenient option for the future?
Lindsay CR; Cassidy J
Expert Rev Gastroenterol Hepatol; 2011 Feb; 5(1):9-19. PubMed ID: 21309667
[TBL] [Abstract][Full Text] [Related]
20. Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H; Hayashi T; Murai S; Shiouchi H; Ando Y; Kumazawa S; Ito K; Ikeda Y; Matsuoka H; Maeda K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2017 May; 79(5):1021-1029. PubMed ID: 28391355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
